Blood Cancer Talks

This is a podcast on latest advances in the understanding and management of blood cancers.

Author: Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
Be a guest on this podcast

Language: en

Genres: Education, Health & Fitness, Medicine

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Trailer:

Get all podcast data

Listen Now...

Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo
Episode 70
Thursday, 22 January, 2026

BloodCancerTalks: ASH 2025 Lymphoma RoundupGuest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of RochesterAbstracts DiscussedFollicular LymphomaEPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FLTheme: Bispecific antibody combinations in R/R FL; comparing to other approaches Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit PatientsMorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligibleEPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patientsR-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patientsTheme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients DLBCL - First-Line TreatmentSMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen)FrontMIND - Tafasitamab-lenalidomide added to R-CHOPTheme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL DLBCL - Relapsed/RefractoryDALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patientsTheme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL Hodgkin LymphomaSWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVDHD21 - 5-year update: PET-adapted BrECADD versus BEACOPPTheme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma Burkitt LymphomaZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory BurkittTheme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma Mantle Cell Lymphoma - First-Line TrAVeRse - Acalabrutinib, venetoclax, rituximabGLOVe - Glofitamab, lenalidomide, venetoclax (high-risk MCL)BOVen - Zanubrutinib, obinutuzumab, venetoclax (older patients)MAVO - Acalabrutinib, venetoclax, obinutuzumabWindow-3 - Acalabrutinib-rituximab followed by brexu-cel (high-risk MCL)Theme: Chemotherapy-free combinations in newly diagnosed mantle cell lymphoma